Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia

American Journal of Hematology

Volumn 86, Issue 11, 2011, Pages 918-922

  Atanackovic, Djordje ^a   Luetkens, Tim ^a   Kloth, Benjamin ^a   Fuchs, Gregor ^a   Cao, Yanran ^a   Hildebrandt, York ^a   Meyer, Sabrina ^a   Bartels, Katrin ^a   Reinhard, Henrike ^a   Lajmi, Nesrine ^a   Hegewisch Becker, Susanna ^b   Schilling, Georgia ^a   Platzbecker, Uwe ^c   Kobbe, Guido ^d   Schroeder, Thomas ^d   Bokemeyer, Carsten ^a   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Private Practice   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CANCER TESTIS ANTIGEN; TRICHOSTATIN A;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE; GENE IDENTIFICATION; GENE INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MAGE A3 GENE; MAJOR CLINICAL STUDY; MALE; PRAME GENE; PRIORITY JOURNAL; ROPN1 GENE; SCP 1 GENE; SLLP1 GENE; SPO11 GENE;

AGED; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BIOLOGICAL MARKERS; BONE MARROW CELLS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DNA METHYLATION; EPIGENOMICS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 80054043545     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22141     Document Type: Article

References (46)

1. Zittoun R, Jehn U, Fiere D, et al. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: A randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood 1989; 73: 896-906.
2. Rees JK, Gray RG, Swirsky D, et al. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; 2: 1236-1241.
3. Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A cancer and leukemia group B study. Blood 1987; 69: 1441-1449.
4. Thomas ED, Buckner CD, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979; 301: 597-599.
5. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14-21.
6. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
7. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
8. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
9. Collins RHJr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
10. Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia-Definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 2006; 91: 1653-1661.
11. Hofmann O, Caballero OL, Stevenson BJ, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA 2008; 105: 20422-20427.
12. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-5337.
13. Old LJ. Cancer/testis (CT) antigens-A new link between gametogenesis and cancer. Cancer Immun 2001; 1: 1.
14. Costa FF, Le Blanc K, Brodin B. Concise review: Cancer/testis antigens, stem cells, and cancer. Stem Cells 2007; 25: 707-711.
15. Sigalotti L, Fratta E, Coral S, et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res 2004; 64: 9167-9171.
16. Luetkens T, Schafhausen P, Uhlich F, et al. Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk Res 2010; 34: 1647-1655.
17. Atanackovic D, Arfsten J, Cao Y, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007; 109: 1103-1112.
18. Atanackovic D, Blum I, Cao Y, et al. Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther 2006; 5: 1218-1225.
19. Pabst C, Zustin J, Jacobsen F, et al. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. Exp Mol Pathol 2010; 89: 175-181.
20. Weber J, Salgaller M, Samid D, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res 1994; 54: 1766-1771.
21. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006; 4: 339-349.
22. Vanhaecke T, Papeleu P, Elaut G, et al. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: Toxicological point of view. Curr Med Chem 2004; 11: 1629-1643.
23. Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495-528.
24. Smiraglia DJ, Rush LJ, Fruhwald MC, et al. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 2001; 10: 1413-1419.
25. Paz MF, Fraga MF, Avila S, et al. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003; 63: 1114-1121.
26. Guinn BA, Gilkes AF, Woodward E, et al. Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005; 333: 703-713.
27. Niemeyer P, Tureci O, Eberle T, et al. Expression of serologically identified tumor antigens in acute leukemias. Leuk Res 2003; 27: 655-660.
28. Lim SH, Austin S, Owen-Jones E, et al. Expression of testicular genes in haematological malignancies. Br J Cancer 1999; 81: 1162-1164.
29. Greiner J, Ringhoffer M, Taniguchi M, et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004; 108: 704-711.
30. Greiner J, Ringhoffer M, Simikopinko O, et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 2000; 28: 1413-1422.
31. Martinez A, Olarte I, Mergold MA, et al. mRNA expression of MAGE-A3 gene in leukemia cells. Leuk Res 2007; 31: 33-37.
32. Chambost H, van Baren N, Brasseur F, et al. MAGE-A genes are not expressed in human leukemias. Leukemia 2001; 15: 1769-1771.
33. Chambost H, Brasseur F, Coulie P, et al. A tumour-associated antigen expression in human haematological malignancies. Br J Haematol 1993; 84: 524-526.
34. Li Z, Li W, Meklat F, et al. A yeast two-hybrid system using Sp17 identified Ropporin as a novel cancer-testis antigen in hematologic malignancies. Int J Cancer 2007; 121: 1507-1511.
35. Wang Z, Zhang Y, Mandal A, et al. The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies. Clin Cancer Res 2004; 10: 6544-6550.
36. Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6: 199-208.
37. Qin Y, Zhu H, Jiang B, et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res 2009; 33: 384-390.
38. van Baren N, Brasseur F, Godelaine D, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999; 94: 1156-1164.
39. Matsushita M, Ikeda H, Kizaki M, et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 2001; 112: 916-926.
40. Quintarelli C, Dotti G, De Angelis B, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008; 112: 1876-1885.
41. Maslak PG, Dao T, Krug LM, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116: 171-179.
42. Ortmann CA, Eisele L, Nuckel H, et al. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Ann Hematol 2008; 87: 809-818.
43. Kuendgen A, Lubbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol 2008; 87: 601-611.
44. Claus R, Almstedt M, Lubbert M. Epigenetic treatment of hematopoietic malignancies: In vivo targets of demethylating agents. Semin Oncol 2005; 32: 511-520.
45. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, et al. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 2010; 34: 899-905.
46. Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116: 1908-1918.